CSBio CSBio

X
[{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Anavo Therapeutics"},{"orgOrder":0,"company":"Frame Cancer Therapeutics","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"$33.3 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Frame Cancer Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"Sotio","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sotio

            Deal Size: $740.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            An additional application of Frame’s technology is the development of personalized cancer vaccines, thereby leveraging the full antigenic potential of a tumor. CureVac will refocus development of personalized cancer vaccines on an mRNA modality.

            Lead Product(s): mRNA Cancer Vaccine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: CureVac

            Deal Size: $33.3 million Upfront Cash: Undisclosed

            Deal Type: Acquisition June 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funds will be used to advance a proprietary drug discovery portfolio in oncology and establish a versatile and robust platform to address the target space broadly across multiple indications.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: M Ventures

            Deal Size: $24.0 million Upfront Cash: Undisclosed

            Deal Type: Financing April 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY